Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
Phase 3
Completed
- Conditions
- Axial SpondyloarthritisEnthesitisPsoriatic Arthritis
- Interventions
- Biological: Secukinumab
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT02771210
- Locations
- 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Phase 4
Completed
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT02768298
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
Phase 2
Terminated
- Conditions
- Transplant Associated Microangiopathy TAM
- Interventions
- Drug: LFG316 active drugOther: Standard of care treatment
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02763644
- Locations
- 🇩🇪
Novartis Investigative Site, Heidelberg, Germany
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
Phase 4
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- Drug: Placebo - Secukinumab (AIN457) 150 mg s.c.
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 211
- Registration Number
- NCT02763046
- Locations
- 🇩🇪
Novartis Investigative Site, Trier, Germany
Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects
Phase 2
Completed
- Conditions
- Atopic Asthma
- Interventions
- Procedure: Blood sampleDevice: POCT device
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 193
- Registration Number
- NCT02758548
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 2
Withdrawn
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02756663
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02756650
- Locations
- 🇹🇷
Novartis Investigative Site, Istanbul, Turkey
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Completed
- Conditions
- HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 440
- Registration Number
- NCT02753686
- Locations
- 🇨🇦
Novartis Investigative Site, Quebec, Canada
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1660
- Registration Number
- NCT02752776
- Locations
- 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom
Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
Phase 3
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02750592
- Locations
- 🇯🇵
Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath